VKORC1 and CYP2C9 Genes Polymorphisms, Affecting the Sensitivity of Anticoagulant Therapy in Patients with Acute Cerebral Circulation Impairment
Abstract
Preliminary data of the frequency of genetic variants VKORC1 and CYP2C9, affecting sensitivity to anticoagulant therapy, in Asian indigenous and Caucasian patients with acute ischemic stroke in Yakutia is presented in this article. The frequencies of increased warfarin sensitivity alleles CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910) and C1173T VKORC1 (rs9934438) polymorphism's variants were determined in the group of 15 patients. CYP2C9 genotyping revealed 3 heterozygous for CYP2C9*1/*2. The allelic variant CYP2C9*3 have not been identified in this group. VKORC1 genotyping revealed 4 heterozygous for 1173CT VKORC1. There were 22.2% carrier with allele CYP2C9*2 and 22.2% with T allele of C1173T VKORC1 polymorphism among Asian indigenous patients. Genotyping of VKORC1 and CYP2C9, including CYP2C9*2 allele, is recommended for personified prevention of the cardioembolic stroke in Yakutia.
About the Authors
S. A. Chugunova
NorthEastern federal university named after M.K. Ammosov; Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Chugunova Sargylana A. – PhD, docent of Department of Neurology and Psychiatry, NorthEastern federal university named after M.K. Ammosov; Scientific researcher of Department of Epidemiology of chronic non-infectious diseases, Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences
4, Sergelyach street, Yakutsk, 677019
T. Y. Nikolayeva
North-Eastern federal university named after M.K. Ammosov
Russian Federation
Russian Federation
Nikolayeva Tatiana Y. – MD, professor, Head of Department of Neurology and Psychiatry
36, Kulakovsky street, Yakutsk, 677007
A. L. Danilova
Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Danilova Anastasya L., Scientific researcher of Molecular Genetics Department, Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences
4, Sergelyach street, Yakutsk, 677019
Kh. A. Kurtanov
Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences; Clinics of Medical Institute, North East Federal University
Russian Federation
Russian Federation
Kurtanov Khariton A., Scientific researcher Molecular Genetics Department, Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences; Scientific researcher Laboratory of Genome Medicine, Clinics of Medical Institute, North East Federal University
4, Sergelyach street, Yakutsk, 677019
N. R. Maksimova
Clinics of Medical Institute, North East Federal University; Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Maksimova Nadezda R. – MD, PHD, Head of Laboratory of Genome Medicine, Clinics of Medical Institute, North East Federal University, Head of Laboratory of Molecular Genetics Department , Federal State Institution "Yakut Scientific Center of complex medical problems", Siberian Branch of Russian Academy of Medical Sciences
46, Kulakovskaya str, Yakutsk, 677019
S. I. Sofronova
Siberian Branch of Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Sofronova Sargylana I. – PhD, Head of Scientific-Organization Department of Federal State Institution "Yakut Scientific Center of complex medical problems"
4, Sergelyach street, Yakutsk, 677019
References
1. A polymorphism in the VKORC1 gene is associated with an interindividual variability in dose-anticoagulant effect of warfarin / G. D`Andrea, RL. D`Ambrosio, P. Di Perna [et al.] // Blood. – 2005.– V.105 (2). – P.645 – 649.
2. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition) / D.E. Singer, G.W. Albers, J.E. Dalen [et al.] // Chest. – 2008.– V.133. Suppl. 6. – P.546 – 592.
3. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese / S.L.Wang, J. Huang, M.D. Lai, J.J. Tsai // Pharmacogenetics. – 1995. – V.5. – P.37 – 42.
4. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose / M. J. Rieder, A.P. Reiner, B.F. Gage [et al.] // N. Engl. J. Med. – 2005. – V.352 (22). – P. 2285 – 2293.
5. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population / Y.R. Yoon, J.H. Shon, M.K. Kim [et al.] // British Journal of Clinical Pharmacology. – 2001.– V. 51(3). – P. 277 – 280.
6. Genetic determinants of response to warfarin during initial anticoagulation. / U. I. Schwarz, M. Ritchie., Y. Bradford [et al.] // N. Engl. J. Med. – 2008.– V.358 (10). – Р. 999 – 1008.
7. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack / K.L. Furie, S.E. Kasner, R.J. Adams [et al.] // Stroke. – 2011. – V. 42. – P.227– 276.
8. Hart, R.G. Meta–analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation / R.G. Hart, L.A. Pearce, M.I. Aguilar // Ann. Intern Med. – 2007.– V.146 (12). – P.857 – 867.
9. Meschia, J.F. Advances in genetics 2010 / J.F. Meschia // Stroke. – 2011. – V.42. – P. 285 – 287.
10. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type / Rost S., Fregin A., Ivaskevicius V. [et al.] // Nature. – 2004. – V. 427. – P.537 – 541.
11. Nasu, K. Genetic analysis of CYP2C9 polymorphism in a Japanese population / K. Nasu, T. Kubota, T. Ishizaki // Pharmacogenetics. – 1997. – V.7 (5). – P.405 – 409.
12. Population variation in VKORC1 haplotype structure / S. Marsh, C.R. King, R.M. PorcheSorbet. [et al.] // Journal of Thrombosis and Haemostasis. – 2006.– V.4 (2). – P.473 – 474.
13. Sanderson, S. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and metaanalysis / S. Sanderson, J. Emery, J. Higgins // Genet Med. – 2005. -7(2) – P.97 –104.
14. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups / N.A. Limdi, M. Wadelius, L. Cavallari [et al.] // Blood. – 2010. – V. 115 (18). – P.3827– 3834.
Review
For citations:
Chugunova S.A., Nikolayeva T.Y., Danilova A.L., Kurtanov Kh.A., Maksimova N.R., Sofronova S.I. VKORC1 and CYP2C9 Genes Polymorphisms, Affecting the Sensitivity of Anticoagulant Therapy in Patients with Acute Cerebral Circulation Impairment. Yakut Medical Journal. 2014;(2):64-67.
Views:
3
Email this article 